Originally from South Devon, Alex completed a BSc and MRes in Pharmacology at Nottingham Trent University. His Masters project was undertaken at the John van Geest Cancer Research Centre, focussing on sensitising cancer stem-like cells to innate immune attack by NK cells.

Alex then worked as a cell line engineer at Horizon Discovery before returning to academia as an advanced research assistant at the Wellcome Sanger Institute where he focused on using whole-genome CRISPR screens to identify novel biomarkers and potential drug targets for sensitising cancers to immunotherapy.

Alongside his work, Alex enjoyed taking part in outreach initiatives, giving talks to primary and secondary school student visits to the Wellcome Sanger Institute and acting as an Employer Advisory Board member at Nottingham Trent University.